SCHEMBL1166848

SCHEMBL1166848

CC(=O)c1ccc(Cn2ccc(NC(=O)c3nc(C)oc3-c3cccc(Cl)c3)n2)o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.56
NPSR1 Q6W5P4 4/20 0.56
TSHR P16473 2/20 0.56
HPGD P15428 2/20 0.56
ALDH1A1 P00352 2/20 0.56
HSD17B10 Q99714 1/20 0.56
FPR2 P25090 5/20 0.51
HCRTR1 O43613 1/20 0.46
HCRTR2 O43614 1/20 0.46
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
GAA P10253 2/20 0.44
TP53 P04637 3/20 0.44
KDM4E B2RXH2 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HTT P42858 1/20 0.43
NPC1 O15118 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1165767 0.92 HCRTR1 (0.55) SMN1; SMN2NPSR1TSHRHPGDALDH1A1
SCHEMBL1166216 0.91 HCRTR1 (0.47) SMN1; SMN2NPSR1TSHRHPGDALDH1A1
SCHEMBL1168026 0.91 SMN1; SMN2 (0.49) SMN1; SMN2NPSR1TSHRHPGDALDH1A1
SCHEMBL1167135 0.90 FPR2 (0.51) SMN1; SMN2NPSR1TSHRHPGDALDH1A1
SCHEMBL1166301 0.90 FPR2 (0.51) SMN1; SMN2NPSR1TSHRHPGDALDH1A1
SCHEMBL1166778 0.89 TP53 (0.56) SMN1; SMN2NPSR1TSHRHPGDALDH1A1
SCHEMBL1166991 0.88 FPR2 (0.54) SMN1; SMN2NPSR1TSHRHPGDALDH1A1
SCHEMBL1167319 0.87 HCRTR1 (0.46) SMN1; SMN2NPSR1TSHRHPGDALDH1A1
SCHEMBL1166206 0.87 HCRTR2 (0.60) SMN1; SMN2NPSR1TSHRHPGDALDH1A1
SCHEMBL2324127 0.87 FPR2 (0.65) SMN1; SMN2NPSR1TSHRHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US claimed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES CYP3A43, CYP1A2, CYP3A5 SMN1; SMN2 4612/4885NPSR1 578/4885TSHR 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.